Veracyte, Inc.
VCYTHealthcareNASDAQDiagnostics & Research · Last scanned May 29, 2026
Scan Results
Daily timeframe1 of 4 indicators bearish as of May 28
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company carries a $3.83B market cap, placing it firmly in the mid-cap category. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis.
Market Cap
$3.83B
Beta
1.89
P/E (TTM)
44.44
P/E (Fwd)
25.19
EPS (TTM)
$1.08
EPS (Fwd)
$1.91
ROE
6.9%
ROA
3.8%
Cash
$439.1M
Total Debt
$39.3M
Free CF
$104.5M
52W Change
80.3%
Annual Financials
Cash vs Debt
With $439.1M in cash and $39.3M in debt, VCYT maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow comes in at $104.5M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. ROE of 6.9% points to modest capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. ROA of 3.8% is on the lower side, which is common in asset-heavy industries. Revenue has grown from $296.5M (2022) to $517.1M (2025), reflecting a 74% increase over the period.
A beta of 1.89 means VCYT is more volatile than average. Investors should be prepared for wider price swings relative to broader indices. With cash comfortably exceeding debt, VCYT has financial flexibility that may help navigate uncertain periods. No single metric tells the full story. Reviewing VCYT's risk profile alongside its fundamentals and technical indicators provides a more complete picture.